FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	VAL							
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name an		2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ADMA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner								
	(Fii MA BIOLO FE ROUTE		3. Date of Earliest Transaction (Month/Day/Year) 03/19/2015								X		er (give title w)		er (specify			
(Street) RAMSEY NJ 074 (City) (State) (Zip					Line) X Form fi							r Joint/Group Filing (Check Applicable n filed by One Reporting Person n filed by More than One Reporting on						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye						Execution Date,		,	3. Transaction Code (Instr. 8) 4. Securities Ar Disposed Of (D					Benefi Owned		ties cially Following	6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)	Ownership
									Code	v	Amount	(A) or (D)	Price			ed ction(s) 3 and 4)		(Instr. 4)
Common Stock, \$0.0001 par value per share 03/19/201							15		P		2,000	A	\$8.498	34 ⁽¹⁾	627,	057(2)(3)	I	Please see footnote ⁽⁴⁾
		Та	ble II								osed of, convertib				wned			,
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expira (Monti	tion D		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		Der Sec	ivative curity ctr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$8.49 to \$8.50 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on March 19, 2015.
- 2. 580,957 of these shares are held by Hariden, LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- 3. 43,200 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- 4. These shares are being purchased by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.

<u>/s/ Adam Grossman</u> 03/23/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.